The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of four new drugs and a new form of Sanofi’s multiple myeloma therapy Sarclisa. The CHMP recommendation covers label and formulation changes that, if adopted by the European Commission, can expand how Sarclisa is administered in routine care. While the report did not list the remaining four drugs in full, the decision provides an important regulatory signal for the multiple myeloma segment—where uptake can hinge on convenience, administration route, and ongoing trial data. For biotech stakeholders monitoring EU timelines, CHMP positive opinions typically precede final European Commission approval and can influence payer and hospital formulary decisions during the subsequent review window. The next steps will determine whether the new Sarclisa presentation advances into broader EU use, impacting competing regimens that depend on treatment logistics as well as efficacy.